Abstracts tagged "Gastrointestinal complications and scleroderma"

Abstract Number: 2937 • 2018 ACR/ARHP Annual Meeting
Anti-Vinculin Antibodies in Systemic Sclerosis (SSc): A Potential Biomarker Linking Vascular and Gastrointestinal System Involvement in Two Phenotypically Distinctive SSc Groups
Yossra A Suliman¹, Suzanne Kafaja², Gianluca Bagnato³, Mohamed Alemam⁴, Isela Valera⁵, Walter Morales⁶, Mark Pimentel⁷, Francesco Del Galdo⁸ and Daniel E. Furst⁹, ¹Rheumatology and Rehabilitation dept., Rheumatology and Rehabilitation dept. Assiut university hospital, Assiut Egypt, Assiut, Egypt, ²Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ³Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴Clinical Pathology and Laboratory Medicine Department, Lecturer, Qena, Egypt, ⁵Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ⁶GI Motility Program, Research associate, Los Angeles, CA, ⁷Gastrointestinal, Cedar Sinai Medical Center, Los Angeles, CA, ⁸Leeds Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁹Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Vinculin is a cytoskeletal protein that plays a major role in cell-cell and cell-extracellular matrix adhesion thus regulating cell growth, migration and function of…
Abstract Number: 2608 • 2013 ACR/ARHP Annual Meeting
Coeliac Disease In Scleroderma – Clinical Features, Frequency and Impact Of Screening In Scleroderma
Alfredo Guillén-Del Castillo¹, Vincent Sobanski², Jennifer Harvey³, Christopher Denton⁴ and Voon H. Ong⁵, ¹Systemic Autoimmune Disease Unit, Department of Internal Medicine, Hospital Universitari Vall d’Hebron, Barcelona, Spain, ²Department of Rheumatology, Royal Free Hospital, London, United Kingdom, ³Clinical Immunology, Royal Free Hospital, London, United Kingdom, ⁴Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ⁵Department of Rheumatology, The Royal Free and University College Medical School, London, United Kingdom
Background/Purpose: Recent studies suggest that coeliac disease (CD) affects 4-7% of Scleroderma (SSc) patients. This association however has not been well characterized in a large…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].